ORIC Pharmaceuticals, Inc. (ORIC)

8.36 -0.41 (-4.67%) As of 12:32PM EDT. Market open.

ORIC Pharmaceuticals, Inc.

240 East Grand Avenue
2nd Floor
South San Francisco, CA 94080
United States
650 388 5600
https://www.oricpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 100

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Richard A. Heyman Ph.D.	Co-Founder, Independent Chairman & Member of Scientific Advisory Board	93k	N/A	1957
Dr. Jacob M. Chacko M.B.A., M.D.	President, CEO & Director	921.32k	N/A	1979
Dr. Pratik S. Multani M.D., M.S.	Chief Medical Officer	686.88k	N/A	1967
Dr. Charles L. Sawyers B.A., M.D., Ph.D.	Co-Founder & Member of Scientific Advisory Board	N/A	N/A	1959
Dr. Scott W. Lowe Ph.D.	Co-Founder & Member of Scientific Advisory Board	N/A	N/A	N/A
Dr. Lori Sickels Friedman Ph.D.	Chief Scientific Officer	N/A	N/A	1964
Dr. Christian V. Kuhlen Esq., J.D., M.D.	General Counsel	N/A	N/A	1973
Mr. Daniel Iazzetti	VP & Head of People	N/A	N/A	N/A
Dr. Edna Chow Maneval	Senior Vice President of Clinical Development	N/A	N/A	1960
Mr. Matthew Panuwat	Chief Business Officer	N/A	N/A	1977

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Corporate governance

ORIC Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 April 2024 is 9. The pillar scores are Audit: 10; Board: 4; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.